Skip to main content

Q1/2023 Results

Fresenius executing on #FutureFresenius: Strong performance of Operating Companies in Q1/23 and structural simplification on track

  • Deconsolidation of Fresenius Medical Care moving ahead as planned

  • Group Revenue increased by 5% to €10.2 billion driven by a broad-based positive performance across the Group

  • Group EBIT in constant currency decreased by 10%  to €908 million in line with expectations. EBIT development of Operating Companies was broadly flat despite negative effects from inflation; Investment Companies clearly dilutive

  • Fresenius Kabi with EBIT margin of 14.5% already within structural band

  • Enhanced transparency with change of Fresenius Kabi’s financial disclosure from a geographic to a product segment view

  • Fresenius Helios with healthy organic revenue growth driven by increasing admissions

  • Structural productivity savings ramping up, ~€130 million already achieved in Q1/23

  • Group outlook confirmed

     

Selected Key Figures Q1/2023

REVENUE

10225 m

+ 5% 1

Q1/22: €9,720 m

EBIT 2

908 m

-10% 1, 4

Q1/22: €1,000 m

NET INCOME 2, 3

389 m

-17% 1, 2

Q1/22: €463 m

EARNINGS PER SHARE 2, 3

0.69 m

-18% 1, 2

Q1/22: €0.83

1 In constant currency

2 Before special items

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

4 According to FY/23 guidance, excluding Provider Relief Fund (PRF) at Fresenius Medical Care

Revenue by business segment

€ in millions Q1/23 Q1/22 ChangeGrowth at constant ratesOrganic growthAcquisitionsDivestitures% of total revenue1

Fresenius Kabi

1,9911,8478%8%7%2%-1%19%

Fresenius Helios

3,0662,9315%5%5%0%0%30%

Fresenius Medical Care

4,7044,5483%2%2%0%0%46%

Fresenius Vamed

58351314%13%13%0%0%5%

Total

10,2259,7205%5%5%1%1%100%

  • 1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group revenue is not possible.

Archive